With over 60 years of experience, bioMérieux is a global leader in in vitro diagnostics. Operating in 45 countries and serving over 160 countries through a wide network of distributors, the company generated €3.1 billion in revenue in 2020, with the majority of sales coming from outside of France. bioMérieux's diagnostic solutions, including systems, reagents, software, and services, are used to determine the source of disease and contamination, primarily for infectious diseases. Additionally, their products are utilized in various industries such as agri-food, pharmaceuticals, and cosmetics to detect microorganisms. The company is listed on the Euronext Paris stock market under the symbol BIM.